[PDF] Top 20 Clinical applications of PD-L1 bioassays for cancer immunotherapy
Has 10000 "Clinical applications of PD-L1 bioassays for cancer immunotherapy" found on our website. Below are the top 20 most common "Clinical applications of PD-L1 bioassays for cancer immunotherapy".
Clinical applications of PD-L1 bioassays for cancer immunotherapy
... in cancer therapy [1 – ...lung cancer as well as a variety of cancer types [4 – 10]. PD-L1 expres- sion varies due to the dynamic tumor microenvironment [11 – ...whether ... See full document
6
Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
... and clinical outcome, low complexity, high re- producibility, low cost, and ease of standardization ...recent clinical research has looked at specific bio- markers to serve as a basis for application of ... See full document
13
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
... for cancer with small molecules and monoclonal antibodies (MoAb) have led to significant improvement in the long-term survival of multiple malignancies [1 – ...of cancer immunotherapy [12, ...of ... See full document
8
Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
... in immunotherapy utilizing immune checkpoint inhibitors (ICIs) have transformed the treatment landscapes of several malignancies in recent ...prostate cancer (mCRPC) infrequently responds to ICIs, while the ... See full document
8
PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer
... and cancer stem cells) [12, ...for clinical ap- plication ...an immunotherapy, CIK-based treatment aims to activate and enhance the body’s immune system to improve its anti-tumor ability, which is ... See full document
14
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
... tumor PD-L1 expression and response to anti-PD-1 agents [17, ...between PD-L1 expression in the TME and clinical responsive to PD-1 blockade has also been shown [28, 29, ... See full document
25
Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy
... ligand PD-L1, leading to reinvigoration of anti-tumor immunity ...der cancer, among other solid tumors. Although tumor PD-L1 expression is associated with response [15], no biomarker of ... See full document
7
Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
... Synthetic peptides have been widely used as targeting moieties and therapeutic reagents to treat various dis- eases, but the applications of peptides as checkpoint in- hibitors remain to be investigated [42]. ... See full document
14
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
... regarding PD-1 and PD-L1 ...between PD-L1 expression and other factors ...of PD-1 expression [1, ...combining immunotherapy with chemotherapy, targeted therapy, and ... See full document
8
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
... Paraneoplastic syndromes (PNSs) are rare autoimmune disorders associated with cancer [7, 8]. The complex pathogenesis of these syndromes is mediated by either sol- uble factors (such as hormones or cytokines ... See full document
12
<p>The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy</p>
... years, immunotherapy targeting immune checkpoints has shed a light on cancer ...of cancer treatment by inhibiting the immune checkpoint programmed cell death protein 1 (PD-1) and cytotoxic ... See full document
9
A phase I/II trial of fixed dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response
... Immunotherapy has lead to breakthroughs in vari- ous solid tumors and can induce spectacular clinical responses. Yet unfortunately, responses are still only seen in the minority of patients. Several ... See full document
9
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
... targets PD-1, has been approved as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with positive PD-L1 ...However, PD-1/PD-L1 checkpoint ... See full document
13
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
... as clinical imaging ...of PD-1- and PD-L1-targeting radiotracers could benefit many cancer ...large clinical trials are first needed to provide convincing evidence that ... See full document
12
From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
... [25]. PD-L1 expression on tumour- infiltrating immune cells was associated with an increased response to atezolizumab, with an ORR of 26% in the IC2/3 population and 18% for those with expression on 1% of ... See full document
15
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
... to PD-1/PD-L1 block- ade is PD-L1 expression, for which there are 4 FDA- approved assays of PD-L1 expression by IHC (Table 1) to help guide treatment decisions for ... See full document
18
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy
... common clinical practice in many forms of cancer to determine disease staging and consecutive therapy options, and when metastases are detectable in the sentinel LN, resection of several, if not all, ... See full document
7
Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials
... This systematic review and meta-analysis resumes the available data from published phase III RCT regarding the OS benefit of anti-PD-1/anti-PD-L1 agents versus docetaxel in patients with progressive ... See full document
11
Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.
... targeting PD-L1 in gastric adenocarcinoma came from the results of pembrolizumab in PD-L1 positive gastric cancer in the KEYNOTE-012 study ...be PD-L1 positive in a ... See full document
42
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
... of PD-L1 in cervical malignancies, and no expression of PD-L1 in normal cervix or benign cervical ...for PD-L1 expression in cervical ...of PD-L1-positive cervical ... See full document
11
Related subjects